Marcin Skrzypski

Marcin Skrzypski

Auto-generated profile, based on publicly available information

Marcin Skrzypski

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
KSKamal S. Saini
Kamal S. Saini
CTC. Taylor
C. Taylor
ARA.-J. Ramirez
A.-J. Ramirez
CPC. Palmieri
C. Palmieri
UGU. Gunnarsson
U. Gunnarsson
EAEvandro de Azambuja
Evandro de Azambuja
The optimal management of patients with breast cancer (BC) requires the expertise of specialists from different disciplines. This has led to the evolution of multidisciplinary teams (MDTs), allowing all key professionals to jointly discuss individual patients and to contribute independently to clinical decisions. Data regarding BC MDTs in different regions and countries are scarce. The investigators of a large global phase III adjuvant BC trial being conducted by the Breast International Group were invited to respond to a questionnaire about the extent, structure, and function of BC MDTs. One hundred and fifty-two responses from 39 countries were received, and remarkable differences were noted in different geographic regions. Sixty-five percent of the respondents from eastern Europe, 63% from western Europe, 35% from Asia, and 25% from South America declared that MDT was a mandatory part of BC care in their country. Ninety percent of the respondents from Europe stated their MDTs met weekly, compared with only half of the respondents from Asia. This survey is perhaps the first large-scale effort to collect information regarding BC MDTs from different parts of the world and provides objective information of frequency, composition, function, and working mechanism of BC MDTs.

7 November 2007 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RRRafael Rosell
Rafael Rosell
MSMarcin Skrzypski
Marcin Skrzypski
EJEwa Jassem
Ewa Jassem
MTMiquel Taron
Miquel Taron
RBRoberta Bartolucci
Roberta Bartolucci
JJJacek Jassem
Jacek Jassem
Although early-stage non-small-cell lung cancer (NSCLC) is considered a potentially curable disease following complete resection, patients have a wide spectrum of survival according to stage (IB, II, IIIA). Within each stage, gene expression profiles can identify patients with a higher risk of recurrence. We hypothesized that altered mRNA expression in nine genes could help to predict disease outcome: excision repair cross-complementing 1 (ERCC1), myeloid zinc finger 1 (MZF1) and Twist1 (which regulate N-cadherin expression), ribonucleotide reductase subunit M1 (RRM1), thioredoxin-1 (TRX1), tyrosyl-DNA phosphodiesterase (Tdp1), nuclear factor of activated T cells (NFAT), BRCA1, and the human homolog of yeast budding uninhibited by benzimidazole (BubR1). We performed real-time quantitative polymerase chain reaction (RT-QPCR) in frozen lung cancer tissue specimens from 126 chemonaive NSCLC patients who had undergone surgical resection and evaluated the association between gene expression levels and survival. For validation, we used paraffin-embedded specimens from 58 other NSCLC patients. A strong inter-gene correlation was observed between expression levels of all genes except NFAT. A Cox proportional hazards model indicated that along with disease stage, BRCA1 mRNA expression significantly correlated with overall survival (hazard ratio [HR], 1.98 [95% confidence interval (CI), 1.11-6]; P = 0.02). In the independent cohort of 58 patients, BRCA1 mRNA expression also significantly correlated with survival (HR, 2.4 [95%CI, 1.01-5.92]; P = 0.04). Overexpression of BRCA1 mRNA was strongly associated with poor survival in NSCLC patients, and the validation of this finding in an independent data set further strengthened this association. Since BRCA1 mRNA expression has previously been linked to differential sensitivity to cisplatin and antimicrotubule drugs, BRCA1 mRNA expression may provide additional information for customizing adjuvant antimicrotubule-based chemotherapy, especially in stage IB, where the role of adjuvant chemotherapy has not been clearly demonstrated.

1 October 2007 in The Lancet Oncology
Verified
Journal Article
Closed access
AMAna Ramírez de Molina
Ana Ramírez de Molina
JSJacinto Sarmentero-Estrada
Jacinto Sarmentero-Estrada
CBCristóbal Belda-Iniesta
Cristóbal Belda-Iniesta
MTMiquel Tarón
Miquel Tarón
VMVictor Ramírez de Molina
Victor Ramírez de Molina
JLJuan Carlos Lacal
Juan Carlos Lacal

31 December 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PRPaul Roepman
Paul Roepman
JJJacek Jassem
Jacek Jassem
ESEgbert F. Smit
Egbert F. Smit
TMThomas Muley
Thomas Muley
JNJacek Niklinski
Jacek Niklinski
Nico Van ZandwijkNico Van Zandwijk
Nico Van Zandwijk
Purpose: Current staging methods are imprecise for predicting prognosis of early-stage non–small-cell lung cancer (NSCLC). We aimed to develop a gene expression profile for stage I and stage II NSCLC, allowing identification of patients with a high risk of disease recurrence within 2 to 3 years after initial diagnosis. Experimental Design: We used whole-genome gene expression microarrays to analyze frozen tumor samples from 172 NSCLC patients (pT1-2, N0-1, M0) from five European institutions, who had undergone complete surgical resection. Median follow-up was 89 months (range, 1.2-389) and 64 patients developed a recurrence. A random two thirds of the samples were assigned as the training cohort with the remaining samples set aside for independent validation. Cox proportional hazards models were used to evaluate the association between expression levels of individual genes and patient recurrence-free survival. A nearest mean analysis was used to develop a gene-expression classifier for disease recurrence. Results: We have developed a 72-gene expression prognostic NSCLC classifier. Based on the classifier score, patients were classified as either high or low risk of disease recurrence. Patients classified as low risk showed a significantly better recurrence-free survival both in the training set (P < 0.001; n = 103) and in the independent validation set (P < 0.01; n = 69). Genes in our prognostic signature were strongly enriched for genes associated with immune response. Conclusions: Our 72-gene signature is closely associated with recurrence-free and overall survival in early-stage NSCLC patients and may become a tool for patient selection for adjuvant therapy.

7 October 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCTRACERx Consortium
TRACERx Consortium
DBDhruva Biswas
Dhruva Biswas
ABAnd Nicolai J. Birkbak
And Nicolai J. Birkbak
RRRachel Rosenthal
Rachel Rosenthal
CHCrispin T. Hiley
Crispin T. Hiley
CSCharles Swanton
Charles Swanton

1 August 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MSMarcin Skrzypski
Marcin Skrzypski
EJEwa Jassem
Ewa Jassem
MTMiquel Taron
Miquel Taron
JSJose Javier Sanchez
Jose Javier Sanchez
PMPedro Mendez
Pedro Mendez
RRRafael Rosell
Rafael Rosell
Purpose: Adjuvant treatment may improve survival in early-stage squamous cell carcinoma (SCC) of the lung; however, the absolute gain is modest and mainly limited to stage II-IIIA. Current staging methods are imprecise indications of prognosis, but high-risk patients can be identified by gene expression profiling and considered for adjuvant therapy. Experimental Design: The expression of 29 genes was assessed by reverse transcriptase quantitative PCR in frozen primary tumor specimens obtained from 66 SCC patients who had undergone surgical resection. Expression values were dichotomized using the median as a cutoff value. We used a risk score to develop a gene expression model for the prediction of survival. Results: The univariate analysis of gene expression in the training cohort identified 10 genes with significant prognostic value: CSF1, EGFR, CA IX, PH4, KIAA0974, ANLN, VEGFC, NTRK1, FN1, and INR1. In the multivariate Cox model, CSF1 (hazard ratio, 3.5; P = 0.005), EGFR (hazard ratio, 2.7; P = 0.02), CA IX (hazard ratio, 0.2; P < 0.0001), and tumor size >4 cm (hazard ratio, 2.7; P = 0.02) emerged as significant markers for survival. The high prognostic value of a risk score based on the expression of the three genes (CSF1, EGFR, and CA IX) was positively validated in a separate cohort of 26 patients in an independent laboratory (P = 0.05). Conclusions: The three-gene signature is strongly associated with prognosis in early-stage SCC. Positive independent validation suggests its suitability for selecting SCC patients with an increased risk of death who might benefit from adjuvant treatment.